Download Files:
568 CAD – 2,384 CADPrice range: 568 CAD through 2,384 CAD
Products Details
Product Description
– Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
Web ID
– T76890
Storage Temperature
– -20℃
Shipping
– Blue Ice
References
– Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.
CAS Number
– 2213450-26-9
Molecular Weight
Compound Purity
– > 95%
Pathway
– Angiogenesis|||JAK/STAT signaling|||Tyrosine Kinase/Adaptors
Product type
– Inhibitory Antibodies
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
Related Products
1000 in stock
1000 in stock
1000 in stock